Companies › Pfizer
89 active drug programs in 535 registered trials: 254 Phase 2, 131 Phase 1, 130 Phase 3, 20 Phase 4; Oncology, Other, Infectious disease, Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Rimegepant Calcitonin gene-related peptide type 1 receptor antagonist | CALCRL | Phase 4 | Acute Treatment of Migraine; Menstrual Migraine; Preventive Treatment of Migraine; Pediatric Migraine … | Nov 2026 |
| Encorafenib Serine/threonine-protein kinase B-raf inhibitor | BRAF | Phase 4 | Solid Tumors; Melanoma; Neoplasms; Metastatic Colorectal Cancer … | Jan 2027 |
| Elranatamab T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent | CD3E, CD3G, CD3D, TNFRSF17 | Phase 4 | Multiple Myeloma; Multiple Myeloma, Newly Diagnosed; Relapsed Refractory Multiple Myeloma (RRMM); Refractory Multiple Myeloma … | May 2027 |
| crizotinib Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor | MET, ALK, EML4, NPM1, ROS1 | Phase 4 | NSCLC | Mar 2028 |
| Tisotumab Vedotin Tubulin inhibitor; Coagulation factor III binding agent | Tubulin, F3 | Phase 4 | Cervical Cancer | Dec 2028 |
| Lorlatinib (PF-06463922) ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor | ALK, EML4 | Phase 4 | Non-Small-Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Ganglioneuroblastoma; Non Small Cell Lung Cancer … | Dec 2028 |
| Binimetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 4 | Solid Tumors; Melanoma | Jul 2029 |
| tilrekimig (PF-07275315) IL-13 receptor alpha-1 antagonist | IL13 | Phase 3 | Atopic Dermatitis; Asthma; Moderate to Severe Chronic Obstructive Pulmonary Disease; Healthy | Nov 2026 |
| Ritlecitinib Tyrosine-protein kinase JAK3 inhibitor; TEC family kinase inhibitor | JAK3, ITK, BMX, TEC, TXK | Phase 3 | Severe Alopecia Areata; Vitiligo; Stable Nonsegmental Vitiligo; Alopecia Areata … | Dec 2026 |
| Sasanlimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | Non-muscle Invasive Bladder Cancer; Urothelial Carcinoma Bladder; Metastatic Renal Cell Carcinoma; Advanced Clear Cell Renal Carcinoma (Ccrcc) | Dec 2026 |
| CMP 001 6-valent OspA-based Lyme disease vaccine | ESR1, OSPAB | Phase 3 | Lyme Disease; Advanced Malignancies; Lyme Borreliosis; Advanced Breast Cancer … | Dec 2026 |
| vepdegestrant Estrogen receptor degrader (SERD) | ESR1 | Phase 3 | Breast Cancer; Healthy Participants | Dec 2026 |
| Palbociclib CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor | CCND1, CDK6, CDK4 | Phase 3 | Breast Cancer; Ewing Sarcoma; Breast Cancer Recurrent; Metastatic Breast Cancer … | Dec 2026 |
| Avelumab Programmed cell death 1 ligand 1 other | CD274 | Phase 3 | Advanced Malignancies | Dec 2026 |
| Lorlatanib ALK inhibitor | ALK | Phase 3 | Advanced Malignancies | Dec 2026 |
| PF04518600 | – | Phase 3 | Advanced Malignancies | Dec 2026 |
| Talazoparib Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor | PARP2, PARP1 | Phase 3 | Advanced Malignancies; mCRPC; Prostate Cancer; Urothelial Carcinoma … | Dec 2026 |
| Utomilumab Tumor necrosis factor receptor superfamily member 9 agonist | TNFRSF9 | Phase 3 | Advanced Malignancies; Stage III Breast Cancer; Breast Cancer; Advanced Malignant Solid Neoplasm | Dec 2026 |
| trastuzumab Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | Colorectal Neoplasms; Uterine Neoplasms; Anatomic Stage IV Breast Cancer AJCC v8; Elderly Females … | Dec 2026 |
| tucatinib Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | HER2 Positive Breast Cancer; Colorectal Neoplasms; HER2-positive Breast Cancer; Uterine Neoplasms … | Dec 2026 |
| Respiratory Syncytial Virus Pre-Fusion Glycoprotein F Fusion glycoprotein F0 vaccine antigen | – | Phase 3 | Lower Respiratory Tract Illness; Respiratory Syncytial Virus (RSV); Adult; RSV Infection … | Jan 2027 |
| Cetuximab Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Neoplasms; Metastatic Colorectal Cancer | Jan 2027 |
| Berobenatide (PF-08653944, MET097) Dual GLP-1R/GIPR agonist | GIPR, GLP1R | Phase 3 | Obesity and Overweight; Obesity; Apnea; Overweight … | Jan 2027 |
| PF-07220060 CDK4 inhibitor | CDK4 | Phase 3 | Breast Cancer; Advanced or Metastatic Breast Cancer; Locally Advanced or Metastatic ER+ HER2- Breast Cancer; Liposarcoma | Feb 2027 |
| Mevrometostat (PF-06821497) | – | Phase 3 | Metastatic Castrate Resistant Prostate Cancer (mCRPC); Metastatic Castration-Resistant Prostate Cancer; Metastatic Castration Sensitive Prostate Cancer (mCSPC); Metastatic Castration Resistant Prostate Cancer (mCRPC) | Feb 2027 |
| PG4 Multivalent pneumococcal conjugate vaccine | – | Phase 3 | Pneumococcal Disease | Mar 2027 |
| tofacitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 3 | Ulcerative Colitis | Mar 2027 |
| Abrocitinib Tyrosine-protein kinase JAK1 inhibitor | JAK1 | Phase 3 | Eczema; Atopic Dermatitis; Post-COVID Condition; Diabetes Mellitus, Type 1 | May 2027 |
| marstacimab Tissue factor pathway inhibitor inhibitor | TFPI | Phase 3 | Hemophilia A; Severe Hemophilia A | May 2027 |
| GBS6: Multivalent Group B streptococcus vaccine 6-valent Group B Streptococcus polysaccharide conjugate vaccine | – | Phase 3 | Pneumococcal Disease; Healthy | Jun 2027 |
| sigvotatug vedotin Integrin beta-6 binding agent | ITGB6 | Phase 3 | Carcinoma, Non-Small-Cell Lung; Carcinoma, Non-Small Cell Lung | Jun 2027 |
| PF-07248144 KAT6 inhibitor | KAT6A, KAT6B | Phase 3 | Breast Cancer; Locally Advanced or Metastatic ER+ HER2- Breast Cancer | Jul 2027 |
| Enzalutamide Androgen Receptor antagonist | AR | Phase 3 | Hormone Sensitive Prostate Cancer | Jul 2027 |
| Leuprolide Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 3 | Hormone Sensitive Prostate Cancer | Jul 2027 |
| Remdesivir RNA-directed RNA polymerase L inhibitor; Replicase polyprotein 1ab inhibitor | 3C, RDRP | Phase 3 | COVID-19 Infection; SARS CoV-2 Post-Acute Sequelae; COVID-19; COVID - 19 … | Sep 2027 |
| ibuzatrelvir | – | Phase 3 | COVID-19 Infection; COVID-19 SARS-CoV-2 Infection | Sep 2027 |
| PF-08634404 Stimulator of Interferon genes (STING) agonist | TMEM173 | Phase 3 | Advanced Non-Small Cell Lung Cancer; Endometrial Neoplasms; Intestinal Neoplasms; Small Cell Lung Cancer … | Oct 2027 |
| Fidanacogene Elaparvovec (PF-06838435) Coagulation factor IX exogenous gene | F9 | Phase 3 | Hemophilia B; Hemophilia A | Feb 2028 |
| PF-08046054 Anti-PD-L1 antibody-drug conjugate | PDCD1LG1 | Phase 3 | Non-small Cell Carcinoma | Mar 2028 |
| Sigvotatug Vedotin Integrin beta-6 binding agent | ITGB6 | Phase 3 | Non-Small Cell Lung Cancer; Advanced/Metastatic Non-Small Cell Lung Cancer | Sep 2028 |
| C. difficile vaccine formulation 1 Toxoid-based Clostridioides difficile vaccine | – | Phase 3 | Clostridoides Difficile Associated Disease | Dec 2028 |
| Etrasimod Sphingosine 1-phosphate receptor Edg-1 agonist; Sphingosine 1-phosphate receptor Edg-6 modulator; Sphingosine 1-phosphate receptor Edg-1 modulator | S1PR1, S1PR4, S1PR5 | Phase 3 | Ulcerative Colitis; Colitis, Ulcerative; Healthy Participant; Pouchitis | Jun 2029 |
| Dazukibart Interferon beta inhibitor | IFNB1 | Phase 3 | Myositis; Dermatomyositis | Jul 2030 |
| PF-06939926 Gene therapy for DMD | – | Phase 3 | Duchenne Muscular Dystrophy | Apr 2039 |
| giroctocogene fitelparvovec AAV5 gene therapy delivering factor VIII | F8 | Phase 3 | Hemophilia A | Feb 2040 |
| Nirmatrelvir (PF-07321332) SARS coronavirus 3C-like proteinase inhibitor | 3CL | Phase 3 | COVID-19; COVID-19, Long Haul | – |
| PF-07055480 / Giroctocogene Fitelparvovec Recombinant AAV2/6 human Factor VIII gene therapy | F8 | Phase 3 | Hemophilia A | – |
| PF-07264660 | – | Phase 2 | Atopic Dermatitis | Nov 2026 |
| PF-07104091 | – | Phase 2 | Small Cell Lung Cancer | Dec 2026 |
| PF-08653945 | – | Phase 2 | Overweight | Jan 2027 |
| Osivelotor | – | Phase 2 | Sickle Cell Disease; Healthy | Feb 2027 |
| PF-07328948 | – | Phase 2 | Heart Failure; Hepatic Impairment; Renal Impairment | Feb 2027 |
| Aztreonam Bacterial penicillin-binding protein inhibitor | – | Phase 2 | Gram-negative Bacterial Infections; Advanced Non Small Cell Lung Cancer | Mar 2027 |
| tisotumab vedotin Tubulin inhibitor; Coagulation factor III binding agent | Tubulin, F3 | Phase 2 | Colorectal Neoplasms | Mar 2027 |
| aztreonam-avibactam (ATM-AVI) β-lactam antibiotic (aztreonam) combined with β-lactamase inhibitor (avibactam) | MMPBLA, CTXM | Phase 2 | Gram-negative Bacterial Infection | Apr 2027 |
| Vaccine Candidate #1 mRNA vaccine targeting influenza virus | – | Phase 2 | Healthy Adults | Jun 2027 |
| ponsegromab GDF15 neutralizing monoclonal antibody | GDF15 | Phase 2 | Cachexia | Jan 2028 |
| PF-08049820 | – | Phase 2 | Atopic Dermatitis | Feb 2028 |
| PF-07850327 / ARV-471 / vepdegestrant PROTAC ER degrader | ESR1 | Phase 2 | Locally Advanced or Metastatic ER+ HER2- Breast Cancer | Aug 2029 |
| Inotuzumab ozogamicin CD22 binding agent | CD22 | Phase 2 | ACUTE LYMPHOBLASTIC LEUKEMIA; B Acute Lymphoblastic Leukemia; B-Cell Acute Lymphoblastic Leukaemia; Leukemia, Acute Lymphoblastic … | May 2033 |
| PF-06835375 CXCR5 inhibitor | CXCR5 | Phase 2 | Primary Immune Thrombocytopenia | – |
| PF-07868489 | – | Phase 2 | Pulmonary Hypertension | – |
| prifetrastat STAT3 inhibitor | – | Phase 1 | Healthy Participant | Dec 2026 |
| PF-07985631 unclear mechanism for IgA nephropathy | – | Phase 1 | Healthy | Dec 2026 |
| PF-08103402 | – | Phase 1 | Healthy Volunteer Study | Mar 2027 |
| PF-08642534 GLP-1 receptor agonist | – | Phase 1 | Obesity | Apr 2027 |
| PF-07832837 | – | Phase 1 | Healthy Participants | Jun 2027 |
| SEA-CD70 anti-CD70 antibody-drug conjugate | CD70 | Phase 1 | Myelodysplastic Syndrome | Jul 2027 |
| Zavegepant (PF-07930207) Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 antagonist; Calcitonin gene-related peptide type 1 receptor antagonist | RAMP1, CALCRL | Phase 1 | Acute Treatment of Migraine; Migraine | Aug 2027 |
| Atirmociclib CDK4/6 inhibitor | CDK4, CDK6 | Phase 1 | Hepatic Impairment | Aug 2027 |
| PF-07799544 BRAF inhibitor | BRAF | Phase 1 | Melanoma | Aug 2027 |
| PF-07799933 BRAF inhibitor | BRAF | Phase 1 | Melanoma | Aug 2027 |
| PF-08065010 | – | Phase 1 | Healthy | Sep 2027 |
| PG4 vaccine in Buffer 1 with high dose PA-002 Multivalent pneumococcal conjugate vaccine | – | Phase 1 | Streptococcus Pneumoniae | Oct 2027 |
| PG4 vaccine in Buffer 1 with low dose PA-001 Multivalent pneumococcal conjugate vaccine | – | Phase 1 | Streptococcus Pneumoniae | Oct 2027 |
| PF-08046054/SGN-PDL1V anti-PD-L1 antibody-drug conjugate | CD274 | Phase 1 | Carcinoma, Non-Small-Cell Lung | Jan 2028 |
| Carfilzomib 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 1 | Multiple Myeloma; Newly Diagnosed; Plasma Cell Myeloma; Newly Diagnosed Multiple Myeloma … | Feb 2028 |
| Maplirpacept CD47-SIRP alpha-directed immune checkpoint inhibitor | CD47 | Phase 1 | Multiple Myeloma | Feb 2028 |
| E coli vaccine 1 Dose A Candidate vaccine against Escherichia coli | – | Phase 1 | Healthy Participants | May 2028 |
| PF-08046876 Antibody-drug conjugate (ADC) | – | Phase 1 | Advanced/Metastatic Solid Tumors | Jul 2028 |
| PF-08046033 | – | Phase 1 | Non-Small-Cell Lung | Jul 2028 |
| PF-08046054/SGN-PDL1V PD-L1-targeted antibody-drug conjugate | PDCD1LG2 | Phase 1 | Advanced/Metastatic Non-Small Cell Lung Cancer | Mar 2029 |
| PF-08032562 | – | Phase 1 | Advanced Breast Cancer | Apr 2029 |
| PF-07994525 | – | Phase 1 | Advanced Malignancies | Jul 2029 |
| PF-08046050 CEACAM5-targeting antibody-drug conjugate | CEACAM5 | Phase 1 | Colorectal Neoplasms | Sep 2029 |
| PF-08052667 Anti-B6N antibody-drug conjugate | B6N | Phase 1 | Non-muscle Invasive Bladder Cancer | Jan 2030 |
| PF-08098488 | – | Phase 1 | Pancreatic Ductal Adenocarcinoma | Jan 2031 |
| PF-07934040 panKRAS inhibitor | KRAS | Phase 1 | Carcinoma, Pancreatic Ductal | – |
| PF-07999415 | – | Phase 1 | Healthy | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT00999804 | trastuzumab | Phase 2 | Breast Cancer | Oncology | Nov 2014 |
| NCT03498378 | Palbociclib | Phase 1 | Head and Neck Squamous Cell Carcinoma | Oncology | Feb 2020 |
| NCT03314636 | Carfilzomib | Phase 2 | Myeloma | Oncology | Nov 2021 |
| NCT04649359 | Elranatamab | Phase 2 | Multiple Myeloma | Oncology | Jun 2022 |
| NCT04678362 | Talazoparib | Phase 2 | Urothelial Carcinoma | Oncology | Jul 2023 |
| NCT05953350 | Palbociclib | Phase 1 | Inhibition of Autophagy Synergizes Anti-tumor Effect | Oncology | May 2024 |
| NCT04370054 | PF-07055480 / Giroctocogene Fitelparvovec | Phase 3 | Hemophilia A | Hematology | Jun 2024 |
| NCT03911973 | Talazoparib | Phase 1 | TNBC - Triple-Negative Breast Cancer | Oncology | Jul 2024 |
| NCT04127110 | Lorlatinib (PF-06463922) | Phase 2 | Non Small Cell Lung Cancer | Oncology | Jul 2024 |
| NCT03709680 | Palbociclib | Phase 2 | Ewing Sarcoma | Oncology | Aug 2024 |
| NCT05041842 | tucatinib | Phase 2 | Metastatic Breast Cancer With a Isolated Brain Progression | Oncology | Apr 2025 |
| NCT02625441 | trastuzumab | Phase 3 | Breast Cancer | Oncology | Jun 2025 |
| NCT03756896 | Carfilzomib | Phase 2 | Plasma Cell Myeloma | Oncology | Jun 2025 |
| NCT06597916 | Respiratory Syncytial Virus Pre-Fusion Glycoprotein F | Phase 2 | RSV Infection | Infectious disease | Aug 2025 |
| NCT02778685 | Palbociclib | Phase 2 | Metastatic Breast Carcinoma | Oncology | Oct 2025 |
| NCT06895733 | Palbociclib | Phase 1 | Solid Tumor, Adult | Oncology | Dec 2025 |
| NCT06193525 | Talazoparib | Phase 2 | Advanced Breast Cancer | Oncology | Dec 2025 |
| NCT05190094 | Palbociclib | Phase 2 | Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer | Oncology | Dec 2025 |
| NCT06973720 | Berobenatide (PF-08653944, MET097) | Phase 2 | Obesity | Metabolic and endocrine | Dec 2025 |
| NCT06158412 | Carfilzomib | Phase 2 | Multiple Myeloma in Relapse | Oncology | Dec 2025 |
| NCT05740943 | Lorlatinib (PF-06463922) | Phase 2 | Stage III NSCLC | Oncology | Dec 2025 |
| NCT06597396 | Abrocitinib | Phase 2 | Post-COVID Condition | Infectious disease | Mar 2026 |
| NCT07406217 | Nirmatrelvir (PF-07321332) | Phase 2 | COVID-19 | Infectious disease | Apr 2026 |
| NCT07406217 | Remdesivir | Phase 2 | COVID-19 | Infectious disease | Apr 2026 |
| NCT03104842 | Carfilzomib | Phase 2 | Multiple Myeloma | Oncology | May 2026 |
| NCT03500445 | Carfilzomib | Phase 2 | Myeloma | Oncology | Jun 2026 |
| NCT06364956 | Palbociclib | Phase 1 | Bladder Cancer | Oncology | Jun 2026 |
| NCT03610438 | Inotuzumab ozogamicin | Phase 2 | Acute Lymphoid Leukemia | Oncology | Jul 2026 |
| NCT05261139 | Nirmatrelvir (PF-07321332) | Phase 3 | COVID-19 | Infectious disease | Jul 2026 |
| NCT05940961 | Inotuzumab ozogamicin | Phase 2 | ALL | Oncology | Aug 2026 |
| NCT06965465 | PF-07999415 | Phase 1 | Healthy | Other | Aug 2026 |
| NCT07153159 | Etrasimod | Phase 1 | Healthy Participant | Other | Sep 2026 |
| NCT05070845 | PF-06835375 | Phase 2 | Primary Immune Thrombocytopenia | Hematology | Sep 2026 |
| NCT06924320 | Berobenatide (PF-08653944, MET097) | Phase 1 | Obesity and Obesity-related Medical Conditions | Metabolic and endocrine | Sep 2026 |
| NCT06924320 | CMP 001 | Phase 1 | Obesity and Obesity-related Medical Conditions | Metabolic and endocrine | Sep 2026 |
| NCT03609047 | Palbociclib | Phase 2 | Breast Cancer Stage II | Oncology | Sep 2026 |
| NCT05573555 | CMP 001 | Phase 1 | Breast Cancer | Oncology | Oct 2026 |
| NCT06447662 | PF-07934040 | Phase 1 | Carcinoma, Pancreatic Ductal | Oncology | Oct 2026 |
| NCT07073820 | PF-07868489 | Phase 2 | Pulmonary Hypertension | Cardiovascular | Oct 2026 |
| NCT04657991 | Encorafenib | Phase 3 | Melanoma | Oncology | Oct 2026 |
| NCT04657991 | Binimetinib | Phase 3 | Melanoma | Oncology | Oct 2026 |
| NCT02877303 | Inotuzumab ozogamicin | Phase 2 | B Acute Lymphoblastic Leukemia | Oncology | Nov 2026 |
| NCT05995964 | tilrekimig (PF-07275315) | Phase 2 | Atopic Dermatitis | Immunology | Nov 2026 |
| NCT05995964 | PF-07264660 | Phase 2 | Atopic Dermatitis | Immunology | Nov 2026 |
| NCT05323955 | tucatinib | Phase 2 | Brain Metastases | Oncology | Nov 2026 |
| NCT02912572 | Talazoparib | Phase 2 | Metastatic Endometrial Cancer | Oncology | Nov 2026 |
| NCT03104491 | Inotuzumab ozogamicin | Phase 1 | Acute Lymphocytic Leukemia | Oncology | Nov 2026 |
| NCT02605486 | Palbociclib | Phase 1 | Metastatic Breast Cancer (MBC) | Oncology | Nov 2026 |
| NCT06249282 | Carfilzomib | Phase 1 | Advanced Lung Non-Small Cell Carcinoma | Oncology | Nov 2026 |
| NCT05159245 | trastuzumab | Phase 2 | Advanced Cancer | Oncology | Nov 2026 |
| NCT06641466 | Rimegepant | Phase 3 | Menstrual Migraine | Neurology | Nov 2026 |
| NCT06832865 | Elranatamab | Phase 2 | Relapsed Refractory Multiple Myeloma (RRMM) | Oncology | Dec 2026 |
| NCT06015542 | Elranatamab | Phase 2 | Multiple Myeloma | Oncology | Dec 2026 |
| NCT07108127 | trastuzumab | Phase 2 | Rectal Cancer | Oncology | Dec 2026 |
| NCT01959698 | Carfilzomib | Phase 1 | CD20 Positive | Oncology | Dec 2026 |
| NCT06992674 | Rimegepant | Phase 2 | Vestibular Migraine | Neurology | Dec 2026 |
| NCT06387121 | Inotuzumab ozogamicin | Phase 2 | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Oncology | Dec 2026 |
| NCT04165317 | Sasanlimab | Phase 3 | Non-muscle Invasive Bladder Cancer | Oncology | Dec 2026 |
| NCT07029711 | Ritlecitinib | Phase 3 | Severe Alopecia Areata | Immunology | Dec 2026 |
| NCT07500506 | CMP 001 | Phase 3 | Lyme Disease | Infectious disease | Dec 2026 |
The 60 nearest readouts of 535 trials; the rest in the app.
Cash and short-term investments of $10.9bn on 2026-09-27; operating cash flow positive
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.